tetano
Editor, Senior Moderator
Cureus
. 2021 Apr 15;13(4):e14505.
doi: 10.7759/cureus.14505.
Secondary Immune Thrombocytopenic Purpura Triggered by COVID-19
Abi Watts[SUP] 1 [/SUP], Kavin Raj[SUP] 1 [/SUP], Pooja Gogia[SUP] 1 [/SUP], Christian C Toquica Gahona[SUP] 1 [/SUP], Marcus Porcelli[SUP] 2 [/SUP]
Affiliations
Abstract
Multiple infectious causes have been implicated with the development of secondary immune thrombocytopenic purpura (ITP). Nevertheless, new pathogens, including coronavirus disease 2019 (COVID-19), are recently being described in its development. A 41-year-old Hispanic male presented to the Emergency Department with a two-day history of bleeding gums and blood-tinged sputum. A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) test was positive on admission. Initial laboratory studies showed severe thrombocytopenia of 3x10[SUP]9[/SUP]/L (150-400x10[SUP]9[/SUP]/L) with no abnormal platelets or schistocytes seen on peripheral blood smear, with normal prothrombin time/international normalized ratio (PT/INR), partial thromboplastin time (PTT) and fibrinogen levels. Secondary causes of thrombocytopenia were ruled out. One unit of single donor platelets was transfused and the patient was treated with intravenous dexamethasone for a total of five days and intravenous immunoglobulin (IVIG) for two days. One week after discharge the patient had a recurrence of epistaxis and hematuria requiring a second course of steroids and IVIG and the decision was made to start the patient on eltrombopag 50mg daily, which maintained his platelet counts within normal limits. COVID-19-associated ITP can be severe and life-threatening and hence warrants rapid and prompt management with steroids and IVIG. In refractory cases, thrombopoietin receptor agonists should be used.
Keywords: covid 19; immune thrombocytopenic purpura; thrombocytopenia.
. 2021 Apr 15;13(4):e14505.
doi: 10.7759/cureus.14505.
Secondary Immune Thrombocytopenic Purpura Triggered by COVID-19
Abi Watts[SUP] 1 [/SUP], Kavin Raj[SUP] 1 [/SUP], Pooja Gogia[SUP] 1 [/SUP], Christian C Toquica Gahona[SUP] 1 [/SUP], Marcus Porcelli[SUP] 2 [/SUP]
Affiliations
- PMID: 34007758
- PMCID: PMC8121211
- DOI: 10.7759/cureus.14505
Abstract
Multiple infectious causes have been implicated with the development of secondary immune thrombocytopenic purpura (ITP). Nevertheless, new pathogens, including coronavirus disease 2019 (COVID-19), are recently being described in its development. A 41-year-old Hispanic male presented to the Emergency Department with a two-day history of bleeding gums and blood-tinged sputum. A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) test was positive on admission. Initial laboratory studies showed severe thrombocytopenia of 3x10[SUP]9[/SUP]/L (150-400x10[SUP]9[/SUP]/L) with no abnormal platelets or schistocytes seen on peripheral blood smear, with normal prothrombin time/international normalized ratio (PT/INR), partial thromboplastin time (PTT) and fibrinogen levels. Secondary causes of thrombocytopenia were ruled out. One unit of single donor platelets was transfused and the patient was treated with intravenous dexamethasone for a total of five days and intravenous immunoglobulin (IVIG) for two days. One week after discharge the patient had a recurrence of epistaxis and hematuria requiring a second course of steroids and IVIG and the decision was made to start the patient on eltrombopag 50mg daily, which maintained his platelet counts within normal limits. COVID-19-associated ITP can be severe and life-threatening and hence warrants rapid and prompt management with steroids and IVIG. In refractory cases, thrombopoietin receptor agonists should be used.
Keywords: covid 19; immune thrombocytopenic purpura; thrombocytopenia.